Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Lambda offers a wide range of bioanalytical capabilities specializing in cell-based assays, biomarkers, immunogenicity, and pharmacokinetics (PK)
Targets and ongoing studies a) PD-1/PD-L1 Inhibitors: Pembrolizumab and nivolumab are PD-1 inhibitors approved for advanced melanoma treatment
JAD 63, 13371346
This flat-fee model removes barriers for patients who require dose escalation, which is common in the first 812 weeks of therapy
BSO treatment showed increased expression of Dnmt3a and 3b and decreased Tet2 and 3 transcripts, and it was not wholly restored after treatment withdrawal at different time points, as was shown by real-time PCR analyses (Fig
US$ 22.85
US$ 20.09
US$ 29.81
US$ 27.50
US$ 27.87
US$ 22.15
